^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thymoma
    Regimen:CAP
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Thymoma: FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS...Preferred (Other Recommended for Thymic Carcinoma)...CAP...Cisplatin 50 mg/m2 IV day 1...Doxorubicin 50 mg/m2 IV day 1...Cyclophosphamide 500 mg/m2 IV day 1...Administered every 3 weeks…